CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 140 enrolled
Drug / intervention
Risperidone implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02773576
NCT02773576Phase 3Completed
CompareCT.gov

A One Year, Open-label, Study to Evaluate the Safety and Tolerability of Risperidone Implants as a Maintenance Treatment in Patients With Schizophrenia

Braeburn Pharmaceuticals·interventional·Posted May 16, 2016·Updated Feb 19, 2020

In Brief

A Phase 3 clinical trial evaluating Risperidone implant for Schizophrenia. Completed, enrolled 140 participants across 1 site.

Detailed Summary

A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 16, 2016
Enrollment StartApr 1, 2016
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.1 years ago

Interventions

Risperidone implantdrug